Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

Russell-Jones, David; Cuddihy, Robert M; Hanefeld, Markolf; Kumar, Ajay; González, Jose G; Chan, Melanie; Wolka, Anne M; Boardman, Marilyn K; DURATION-4 Study Group,; Mathieu, Chantal

doi:10.2337/dc11-1107

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

Author:

Russell-Jones, David

Cuddihy, Robert M ; Hanefeld, Markolf ; Kumar, Ajay ; González, Jose G ; Chan, Melanie ; Wolka, Anne M ; Boardman, Marilyn K ; DURATION-4 Study Group, ; Mathieu, Chantal

Keywords:

Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, INITIAL COMBINATION THERAPY, GLYCEMIC CONTROL, OPEN-LABEL, INSULIN SENSITIVITY, PARALLEL-GROUP, VILDAGLIPTIN, TOLERABILITY, GLICLAZIDE, MELLITUS, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Exenatide, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Pioglitazone, Pyrazines, Sitagliptin Phosphate, Thiazolidinediones, Treatment Outcome, Triazoles, Venoms, DURATION-4 Study Group, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes.